-
1
-
-
84895821627
-
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010
-
Denniston, M.M., Jiles, R.B., Drobeniuc, J., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160:5 (2014), 293–300.
-
(2014)
Ann Intern Med
, vol.160
, Issue.5
, pp. 293-300
-
-
Denniston, M.M.1
Jiles, R.B.2
Drobeniuc, J.3
-
2
-
-
0026506727
-
Characteristics of intravenous drug users by history of arrest and treatment for drug use
-
Alcabes, P., Vlahov, D., Anthony, J.C., Characteristics of intravenous drug users by history of arrest and treatment for drug use. J Nerv Ment Dis 180:1 (1992), 48–54.
-
(1992)
J Nerv Ment Dis
, vol.180
, Issue.1
, pp. 48-54
-
-
Alcabes, P.1
Vlahov, D.2
Anthony, J.C.3
-
3
-
-
84931578378
-
Incarceration and injection drug use in Baltimore, Maryland
-
Genberg, B.L., Astemborski, J., Vlahov, D., et al. Incarceration and injection drug use in Baltimore, Maryland. Addiction 110:7 (2015), 1152–1159.
-
(2015)
Addiction
, vol.110
, Issue.7
, pp. 1152-1159
-
-
Genberg, B.L.1
Astemborski, J.2
Vlahov, D.3
-
4
-
-
85021122879
-
A national strategy for the elimination of hepatitis B and C: phase two report
-
National Academies Press Washington, DC
-
National Academies of Sciences Engineering, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. 2017, National Academies Press, Washington, DC.
-
(2017)
-
-
-
5
-
-
85047227293
-
-
World prison brief, Webpage of the International Centre for Prison Studies, University of London. Available at: Accessed February 3.
-
World prison brief, Webpage of the International Centre for Prison Studies, University of London. Available at: http://www.prisonstudies.org/world-prison-brief-data. Accessed February 3, 2018.
-
(2018)
-
-
-
6
-
-
81555207211
-
The diversity of release patterns for jail detainees: implications for public health interventions
-
Spaulding, A.C., Perez, S.D., Seals, R.M., et al. The diversity of release patterns for jail detainees: implications for public health interventions. Am J Public Health 101:Suppl 1 (2011), S347–S352.
-
(2011)
Am J Public Health
, vol.101
, pp. S347-S352
-
-
Spaulding, A.C.1
Perez, S.D.2
Seals, R.M.3
-
7
-
-
85044932431
-
Jail, an unappreciated medical home: assessing the feasibility of a strengths-based case management intervention to improve the care retention of HIV-infected persons once released from jail
-
Spaulding, A.C., Drobeniuc, A.M., Frew, P.M., et al. Jail, an unappreciated medical home: assessing the feasibility of a strengths-based case management intervention to improve the care retention of HIV-infected persons once released from jail. PLoSOne, 13(3), 2018, e0191643.
-
(2018)
PLoSOne
, vol.13
, Issue.3
, pp. e0191643
-
-
Spaulding, A.C.1
Drobeniuc, A.M.2
Frew, P.M.3
-
8
-
-
84894283982
-
Hepatitis C seroprevalence among prison inmates since 2001: still high but declining
-
Varan, A.K., Mercer, D.W., Stein, M.S., et al. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep 129:2 (2014), 187–195.
-
(2014)
Public Health Rep
, vol.129
, Issue.2
, pp. 187-195
-
-
Varan, A.K.1
Mercer, D.W.2
Stein, M.S.3
-
9
-
-
85020284084
-
Prisoners in 2015
-
US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics Washington, DC NCJ 250229. Available at: Accessed January 20, 2017
-
Carson, E.A., Anderson, E., Prisoners in 2015. 2016, US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, Washington, DC NCJ 250229. Available at: https://www.bjs.gov/index.cfm?ty=pbdetail&iid=5869 Accessed January 20, 2017.
-
(2016)
-
-
Carson, E.A.1
Anderson, E.2
-
10
-
-
84994234383
-
New hepatitis C drugs are very costly and unavailable to many state prisoners
-
Beckman, A.L., Bilinski, A., Boyko, R., et al. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff 35:10 (2016), 1893–1901.
-
(2016)
Health Aff
, vol.35
, Issue.10
, pp. 1893-1901
-
-
Beckman, A.L.1
Bilinski, A.2
Boyko, R.3
-
11
-
-
84878824929
-
Impact of new therapeutics for hepatitis C virus infection in incarcerated populations
-
Spaulding, A., Kim, A., Harzke, A., et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med 21:1 (2012), 27–35.
-
(2012)
Top Antivir Med
, vol.21
, Issue.1
, pp. 27-35
-
-
Spaulding, A.1
Kim, A.2
Harzke, A.3
-
12
-
-
85028851762
-
HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community's infections
-
Spaulding, A.C., Anderson, E.J., Khan, M.A., et al. HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community's infections. AIDS Rev 19:3 (2017), 134–147.
-
(2017)
AIDS Rev
, vol.19
, Issue.3
, pp. 134-147
-
-
Spaulding, A.C.1
Anderson, E.J.2
Khan, M.A.3
-
13
-
-
27944460083
-
Hepatitis testing and treatment in state prisons
-
US Department of Justice, Office of Justice Programs Washington, DC
-
Beck, A.J., Maruschak, L.M., Hepatitis testing and treatment in state prisons. 2004, US Department of Justice, Office of Justice Programs, Washington, DC.
-
(2004)
-
-
Beck, A.J.1
Maruschak, L.M.2
-
14
-
-
84966430278
-
Rising mortality associated with hepatitis C virus in the United States, 2003–2013
-
Ly, K.N., Hughes, E.M., Jiles, R.B., et al. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis 62:10 (2016), 1287–1288.
-
(2016)
Clin Infect Dis
, vol.62
, Issue.10
, pp. 1287-1288
-
-
Ly, K.N.1
Hughes, E.M.2
Jiles, R.B.3
-
15
-
-
85047202833
-
-
Estelle v. Gamble 429 U.S. 97
-
Estelle v. Gamble 429 U.S. 97 (1976).
-
(1976)
-
-
-
16
-
-
84955254471
-
Prevention of hepatitis C by screening and treatment in US prisons
-
He, T., Li, K., Roberts, M., et al. Prevention of hepatitis C by screening and treatment in US prisons. Ann Intern Med 164:2 (2016), 84–92.
-
(2016)
Ann Intern Med
, vol.164
, Issue.2
, pp. 84-92
-
-
He, T.1
Li, K.2
Roberts, M.3
-
17
-
-
84887020007
-
Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals
-
Martin, N.K., Vickerman, P., Grebely, J., et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58:5 (2013), 1598–1609.
-
(2013)
Hepatology
, vol.58
, Issue.5
, pp. 1598-1609
-
-
Martin, N.K.1
Vickerman, P.2
Grebely, J.3
-
18
-
-
84921051337
-
High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia
-
Cepeda, J.A., Niccolai, L.M., Lyubimova, A., et al. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend 147 (2015), 196–202.
-
(2015)
Drug Alcohol Depend
, vol.147
, pp. 196-202
-
-
Cepeda, J.A.1
Niccolai, L.M.2
Lyubimova, A.3
-
19
-
-
85047222955
-
-
Federal Bureau of Prisons. Evaluation and management of chronic hepatitis C virus (HCV) infection. Clinical guidance. 2016. Available at: Accessed September 7.
-
Federal Bureau of Prisons. Evaluation and management of chronic hepatitis C virus (HCV) infection. Clinical guidance. 2016. Available at: https://www.bop.gov/resources/pdfs/hepatitis_c.pdf. Accessed September 7, 2017.
-
(2017)
-
-
-
20
-
-
85047210551
-
-
Committee on Finance, United States Senate. The price of sovaldi and its impact on the U.S. health care system. 2015. Available at: Accessed February 24.
-
Committee on Finance, United States Senate. The price of sovaldi and its impact on the U.S. health care system. 2015. Available at: https://www.finance.senate.gov/download/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report. Accessed February 24, 2017.
-
(2017)
-
-
-
21
-
-
84867288022
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
-
Smith, B.D., Morgan, R.L., Beckett, G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61:RR-4 (2012), 1–32.
-
(2012)
MMWR Recomm Rep
, vol.61
, Issue.RR-4
, pp. 1-32
-
-
Smith, B.D.1
Morgan, R.L.2
Beckett, G.A.3
-
22
-
-
84881637752
-
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement
-
Moyer, V.A., Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159:5 (2013), 349–357.
-
(2013)
Ann Intern Med
, vol.159
, Issue.5
, pp. 349-357
-
-
Moyer, V.A.1
-
23
-
-
11244331541
-
Elevated prevalence of hepatitis C infection in users of United States veterans medical centers
-
Dominitz, J.A., Boyko, E.J., Koepsell, T.D., et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 41:1 (2005), 88–96.
-
(2005)
Hepatology
, vol.41
, Issue.1
, pp. 88-96
-
-
Dominitz, J.A.1
Boyko, E.J.2
Koepsell, T.D.3
-
24
-
-
79952223130
-
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis
-
Lin, Z.H., Xin, Y.N., Dong, Q.J., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53:3 (2011), 726–736.
-
(2011)
Hepatology
, vol.53
, Issue.3
, pp. 726-736
-
-
Lin, Z.H.1
Xin, Y.N.2
Dong, Q.J.3
-
25
-
-
84940001963
-
Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system
-
Kuncio, D.E., Newbern, E.C., Fernandez-Viña, M.H., et al. Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health 92:2 (2015), 379–386.
-
(2015)
J Urban Health
, vol.92
, Issue.2
, pp. 379-386
-
-
Kuncio, D.E.1
Newbern, E.C.2
Fernandez-Viña, M.H.3
-
26
-
-
84901020258
-
Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004–2012: limitations of 1945–1965 birth cohort screening in correctional settings
-
Larney, S., Mahowald, M.K., Scharff, N., et al. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004–2012: limitations of 1945–1965 birth cohort screening in correctional settings. Am J Public Health 106:6 (2014), e69–74.
-
(2014)
Am J Public Health
, vol.106
, Issue.6
, pp. e69-74
-
-
Larney, S.1
Mahowald, M.K.2
Scharff, N.3
-
27
-
-
84977104427
-
Performance of risk-based and birth-cohort strategies for identifying hepatitis C virus infection among people entering prison, Wisconsin, 2014
-
Stockman, L.J., Greer, J., Holzmacher, R., et al. Performance of risk-based and birth-cohort strategies for identifying hepatitis C virus infection among people entering prison, Wisconsin, 2014. Public Health Rep 131:4 (2016), 544–551.
-
(2016)
Public Health Rep
, vol.131
, Issue.4
, pp. 544-551
-
-
Stockman, L.J.1
Greer, J.2
Holzmacher, R.3
-
28
-
-
85060903584
-
HIV in prison
-
Bureau of Justice Statistics Washington, DC NCJ 250641. Available at: Accessed October 10, 2017
-
Maruschak, L.M., Bronson, J., HIV in prison. 2017, Bureau of Justice Statistics, Washington, DC NCJ 250641. Available at: https://www.bjs.gov/content/pub/pdf/hivp15st.pdf Accessed October 10, 2017.
-
(2017)
-
-
Maruschak, L.M.1
Bronson, J.2
-
29
-
-
85007137332
-
A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections
-
Beckwith, C.G., Kurth, A.E., Bazerman, L.B., et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J Public Health (Oxf) 38:1 (2016), 130–137.
-
(2016)
J Public Health (Oxf)
, vol.38
, Issue.1
, pp. 130-137
-
-
Beckwith, C.G.1
Kurth, A.E.2
Bazerman, L.B.3
-
30
-
-
34250334182
-
Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program
-
Klein, S.J., Wright, L.N., Birkhead, G.S., et al. Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program. Public Health Rep 122:Suppl 2 (2007), 83–88.
-
(2007)
Public Health Rep
, vol.122
, pp. 83-88
-
-
Klein, S.J.1
Wright, L.N.2
Birkhead, G.S.3
-
31
-
-
84883419062
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review
-
Chou, R., Wasson, N., Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 158:11 (2013), 807–820.
-
(2013)
Ann Intern Med
, vol.158
, Issue.11
, pp. 807-820
-
-
Chou, R.1
Wasson, N.2
-
32
-
-
0037418133
-
Treatment of chronic hepatitis C in a state correctional facility
-
Allen, S.A., Spaulding, A.C., Osei, A.M., et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 138:3 (2003), 187–190.
-
(2003)
Ann Intern Med
, vol.138
, Issue.3
, pp. 187-190
-
-
Allen, S.A.1
Spaulding, A.C.2
Osei, A.M.3
-
33
-
-
85047196669
-
-
Characterization of a population with hepatitis C infection in a U.S. state prison. 6th International Symposium on hepatitis care in substance users. Jersey City, NJ, September 6–8.
-
Assoumou SA, Wang J, Tsui J, et al. Characterization of a population with hepatitis C infection in a U.S. state prison. 6th International Symposium on hepatitis care in substance users. Jersey City, NJ, September 6–8, 2017.
-
(2017)
-
-
Assoumou, S.A.1
Wang, J.2
Tsui, J.3
-
34
-
-
85007478352
-
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
-
Rosenthal, E.S., Graham, C.S., Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer, 11(1), 2016, 24.
-
(2016)
Infect Agent Cancer
, vol.11
, Issue.1
, pp. 24
-
-
Rosenthal, E.S.1
Graham, C.S.2
-
35
-
-
85027976008
-
Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6
-
He, T., Lopez-Olivo, M.A., Hur, C., et al. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther 46:8 (2017), 711–721.
-
(2017)
Aliment Pharmacol Ther
, vol.46
, Issue.8
, pp. 711-721
-
-
He, T.1
Lopez-Olivo, M.A.2
Hur, C.3
-
36
-
-
85008448661
-
Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving
-
Chhatwal, J., He, T., Hur, C., et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol 15:6 (2017), 827–837.e8.
-
(2017)
Clin Gastroenterol Hepatol
, vol.15
, Issue.6
, pp. 827-837.e8
-
-
Chhatwal, J.1
He, T.2
Hur, C.3
-
37
-
-
85047222474
-
-
U.S.C. 1396r-8(k)(1).
-
U.S.C. 1396r-8(k)(1).
-
-
-
-
38
-
-
85047209615
-
-
C.F.R. 447.504.
-
C.F.R. 447.504.
-
-
-
-
39
-
-
84896449505
-
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries
-
Hill, A., Khoo, S., Fortunak, J., et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 58:7 (2014), 928–936.
-
(2014)
Clin Infect Dis
, vol.58
, Issue.7
, pp. 928-936
-
-
Hill, A.1
Khoo, S.2
Fortunak, J.3
-
40
-
-
84925374207
-
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
-
van de Ven, N., Fortunak, J., Simmons, B., et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61:4 (2015), 1174–1182.
-
(2015)
Hepatology
, vol.61
, Issue.4
, pp. 1174-1182
-
-
van de Ven, N.1
Fortunak, J.2
Simmons, B.3
-
41
-
-
85047197877
-
-
U.S.C. 1395 w-3a.
-
U.S.C. 1395 w-3a.
-
-
-
-
42
-
-
85047221258
-
-
U.S.C. 8126.
-
U.S.C. 8126.
-
-
-
-
43
-
-
85047192141
-
-
U.S.C. 256b.
-
U.S.C. 256b.
-
-
-
-
44
-
-
85047223341
-
-
U.S.C. 1396r-8.
-
U.S.C. 1396r-8.
-
-
-
-
45
-
-
85047228932
-
-
U.S.C. 1396r-8 (c)(1)(C)(i).
-
U.S.C. 1396r-8 (c)(1)(C)(i).
-
-
-
-
46
-
-
85033467011
-
A prescription for excessive drug pricing: leveraging government patent use for health
-
Available at
-
Brennan, H., Kapczynski, A., Monahan, C.H., et al. A prescription for excessive drug pricing: leveraging government patent use for health. Yale Journal of Law & Technology, 18(1), 2016, 7 Available at: http://digitalcommons.law.yale.edu/yjolt/vol18/iss1/7.
-
(2016)
Yale Journal of Law & Technology
, vol.18
, Issue.1
, pp. 7
-
-
Brennan, H.1
Kapczynski, A.2
Monahan, C.H.3
-
47
-
-
85047185493
-
High cost of new HCV drugs strains prison budgets, locks many out of care
-
Available at: Accessed September 13, 2016
-
Fields, G., Lofuts, P., High cost of new HCV drugs strains prison budgets, locks many out of care. Wall Street Journal, 2016 Available at: https://www.wsj.com/articles/high-cost-of-new-hepatitis-c-drugs-strains-prison-budgets-locks-many-out-of-cure-1473701644 Accessed September 13, 2016.
-
(2016)
Wall Street Journal
-
-
Fields, G.1
Lofuts, P.2
-
48
-
-
85047202663
-
-
C.F.R. 447.502.
-
C.F.R. 447.502.
-
-
-
-
49
-
-
85047177385
-
-
U.S.C. 1396r-8(c)(1)(D)(i).
-
U.S.C. 1396r-8(c)(1)(D)(i).
-
-
-
-
50
-
-
85047222554
-
-
U.S.C. 1396r-8(c)(1)(D)(ii).
-
U.S.C. 1396r-8(c)(1)(D)(ii).
-
-
-
-
51
-
-
85047181199
-
-
Letter to Rebekah E. Gee, Secretary of Health, State of Louisiana. 2017. Available at: Accessed October 10.
-
Sharfstein JM, GA, JMB, et al. Letter to Rebekah E. Gee, Secretary of Health, State of Louisiana. 2017. Available at: http://ldh.la.gov/assets/docs/HepatitisC/ResponsememotoSecretaryGeeHCV.pdf. Accessed October 10, 2010.
-
(2010)
-
-
Sharfstein, J.M.1
GA, J.M.B.2
-
52
-
-
84877261106
-
Cost-effectiveness of screening for chronic hepatitis C infection in the United States
-
Eckman, M.H., Talal, A.H., Gordon, S.C., et al. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 56:10 (2013), 1382–1393.
-
(2013)
Clin Infect Dis
, vol.56
, Issue.10
, pp. 1382-1393
-
-
Eckman, M.H.1
Talal, A.H.2
Gordon, S.C.3
-
53
-
-
84863393363
-
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings
-
Rein, D.B., Smith, B.D., Wittenborn, J.S., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 156:4 (2012), 263–270.
-
(2012)
Ann Intern Med
, vol.156
, Issue.4
, pp. 263-270
-
-
Rein, D.B.1
Smith, B.D.2
Wittenborn, J.S.3
-
54
-
-
84859947750
-
Economic model of a birth cohort screening program for hepatitis C virus
-
McGarry, L.J., Pawar, V.S., Panchmatia, H.R., et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 55:5 (2012), 1344–1355.
-
(2012)
Hepatology
, vol.55
, Issue.5
, pp. 1344-1355
-
-
McGarry, L.J.1
Pawar, V.S.2
Panchmatia, H.R.3
-
55
-
-
84875287973
-
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
-
Liu, S., Cipriano, L.E., Holodniy, M., et al. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One, 8(3), 2013, e58975.
-
(2013)
PLoS One
, vol.8
, Issue.3
, pp. e58975
-
-
Liu, S.1
Cipriano, L.E.2
Holodniy, M.3
-
56
-
-
84978300317
-
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis
-
Martin, N.K., Vickerman, P., Brew, I.F., et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology 63:6 (2016), 1796–1808.
-
(2016)
Hepatology
, vol.63
, Issue.6
, pp. 1796-1808
-
-
Martin, N.K.1
Vickerman, P.2
Brew, I.F.3
-
57
-
-
84884549621
-
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons
-
[pii:e003153]
-
Martin, N.K., Hickman, M., Miners, A., et al. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 3(8), 2013 [pii:e003153].
-
(2013)
BMJ Open
, vol.3
, Issue.8
-
-
Martin, N.K.1
Hickman, M.2
Miners, A.3
-
58
-
-
85023169648
-
Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study
-
Cepeda, J.A., Thomas, D.L., Astemborski, J., et al. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study. Clin Infect Dis 65:2 (2017), 235–243.
-
(2017)
Clin Infect Dis
, vol.65
, Issue.2
, pp. 235-243
-
-
Cepeda, J.A.1
Thomas, D.L.2
Astemborski, J.3
-
59
-
-
85047203434
-
-
Available at: Accessed March 19.
-
Available at: https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html. Accessed March 19, 2018.
-
(2018)
-
-
-
60
-
-
85047208634
-
-
C.F.R. 447.509 (a) (1).
-
C.F.R. 447.509 (a) (1).
-
-
-
-
61
-
-
85047195732
-
-
C.F.R. 447.509.
-
C.F.R. 447.509.
-
-
-
-
62
-
-
85047185947
-
-
C.F.R. 447.509 (a) (6).
-
C.F.R. 447.509 (a) (6).
-
-
-
-
63
-
-
85047197404
-
-
U.S.C. 1396r-8 (k)(3).
-
U.S.C. 1396r-8 (k)(3).
-
-
-
-
64
-
-
85047211669
-
-
Veterans Health Care Act of 1992, Pub. L. No. 102-585 §602, 106 Stat. 4943.
-
Veterans Health Care Act of 1992, Pub. L. No. 102-585 §602, 106 Stat. 4943, 4967–4971 (1992).
-
(1992)
, pp. 4967-4971
-
-
-
65
-
-
85047225012
-
-
U.S.C. 1396 r -8(c)(1)(C)(ii)(III).
-
U.S.C. 1396 r -8(c)(1)(C)(ii)(III).
-
-
-
-
66
-
-
17144429966
-
Pharmaceutical discounts under federal law: state program opportunities
-
Pharmaceuticals and Indigent Care Program, Public Health Institute Oakland (CA)
-
von Oehsen, W.H., Ashe M, Duke K., Pharmaceutical discounts under federal law: state program opportunities. 2001, Pharmaceuticals and Indigent Care Program, Public Health Institute, Oakland (CA).
-
(2001)
-
-
von Oehsen, W.H.1
Ashe M, D.K.2
|